Keeping Up with Legislative and Regulatory Matters

[L4] Drug Pricing Reform Efforts: The Blueprint Turns 1 Year Old

ACPE UAN: 0233-0000-19-036-L04-P | Contact Hours: 1.25 | Activity Type: Knowledge-based

Faculty(s)

• 

  Melissa Andel, MPP

  Vice President of Health Policy
  Applied Policy
  Alexandria, Virginia

Moderator(s)

• DW

  David Wamble, PhD

  Director, Health Economics
  RTI Health Solutions
  Research Triangle Park, North Carolina

Since President Trump released his administration’s Drug Pricing Blueprint in May 2018, health care stakeholders have been anticipating changes to drug pricing policy. Americans have identified prescription drug prices as a top public policy issue, and Congress and the White House are trying to provide patient relief. Over the past 10 months, the Centers for Medicare and Medicaid Services (CMS) and the Office of the Inspector General have issued many policies and regulations to lower drug costs, some of which are likely to have bigger impacts than others. At the same time, states have been busy introducing reforms of their own. This session will help you catch up on what has happened, what has been proposed, and what we might expect as we look toward 2020.

Learning Objectives:

At the completion of this activity, participants should be able to:

1. Review the U.S. drug pricing system, including how different stakeholders negotiate net costs.
2. Review legislative and regulatory updates to drug pricing at the state and federal level.
3. Summarize key pillars of the drug pricing blueprint impacting managed care pharmacy.
4. Discuss potential future policies, including the impact that the 2018 elections may have moving forward.